|
Apex Group Ltd. ("Apex Group" or "The Group"), a global financial services provider, today announced its expanded remit to support BrightEdge LLC, the impact investment and venture capital arm of the American Cancer Society ("ACS").
BrightEdge invests the ACS Impact Venture Fund in for-profit early-stage companies that are developing cutting-edge cancer-focused therapies, diagnostics, devices, and technologies to give all people the opportunity to detect, treat and survive cancer. Financial returns generated from investments will be reinvested in the Fund and/or returned to ACS as a diversified and sustainable source of funding for ACS' mission of reducing cancer mortality, ending pain and suffering, and advancing health equity.
Apex Group was...
|